|
|
|
|
|
|||||||
|
Session 61
Poster Session
Antiretroviral Chemotherapy in Previously Treated Individuals 4:30-6:30 pm 4E-F |
to view the poster for an abstract.| 413-W. | Tenofovir DF: A 48-Week Final Analysis from a Phase III Randomized, Double Blind Placebo Controlled Study in Antiretroviral Experienced Patients K. Squires*1, G. Pierone2, D. Berger3, C. Steinhart4, N. Bellos5, S. L. Becker6, S. S. Chen7, M. D. Miller7, D. F. Coakley7, and A. Cheng7 for the Study 907 Team 1Univ. of Southern California, Los Angeles; 2Treasure Coast Infectious Disease Consultants, Vero Beach, FL; 3Northstar Med. Ctr., Chicago, IL; 4Steinhart Med., Miami, FL; 5Dallas, TX; 6Pacific Horizon Med. Ctr., San Francisco, CA; and 7Gilead Sci., Inc., Foster City, CA
| ||
| 414-W. | Final 48-Week Genotypic and Phenotypic Analyses of Study 907: Tenofovir DF (TDF) Added to Stable Background Regimens N. A. Margot, A. Johnson, A. Cheng, D. F. Coakley, and M. D. Miller* Gilead Sci., Inc., Foster City, CA
| ||
| 415-W. | The Viread Expanded Access Program (EAP): Safety and Efficacy of Tenofovir Disoproxil Fumarate (TDF) in Antiretroviral Treatment (ART)-Experienced Patients S. Follansbee*1, J. Reynes2, M. Nelson3, B. Clotet4, A. Lazzarin5, A. Adam6, S. Van Doren7, R. Buffels7, S. Barriere7, L. Zagury7, I. Miranski7, and J. Rooney7 1Kaiser Permanente Med. Ctr., San Francisco, CA; 2Hosp. Gui de Chauliac, Montpellier, France; 3Chelsea and Westminster Hosp., London, UK; 4Hosp. Germans Trias i Pujol, Barcelona, Spain; 5Ospedale San Raffaele, Milano, Italy; 6IPM-Study Ctr., Hamburg, Germany; and 7Gilead Sci., Foster City, CA and Paris, France
| ||
| 416-W. | Safety Profile of Tenofovir DF in Antiretroviral-Experienced Patients from Randomized, Double-Blind, Placebo-Controlled Clinical Trials A. Cheng*, S. Barriere, D. F. Coakley, S. S. Chen, M. Wulfsohn, and J. J. Toole Gilead Sci., Inc., Foster City, CA
| ||
| 417-W. | A Week-48 Assessment of High Strength T-20 Formulations in Multi-Class Experienced Patients L. J. Wheat*1, J. Lalezari2, M. Kilby3, D. Wheeler4, M. Salgo5, R. DeMasi6, and J. Delehanty6 1Indiana Univ., Indianapolis; 2Quest Clin. Res., San Francisco, CA; 3Univ. Alabama, Birmingham; 4Annandale, VA; 5Hoffmann-La Roche, Nutley, NJ; and 6Trimeris, Inc., Durham, NC
| ||
| 418-W. | A Week 48 Assessment of a Randomized, Controlled, Open-Label Phase II Trial (T20-206) Evaluating 3 Doses of T-20 in PI-Experienced, NNRTI-Naïve Patients Infected with HIV-1 J. Lalezari*1, E. DeJesus2, D. Northfelt3, G. Richmond4, J. Delehanty5, R. DeMasi5, and M. Salgo6 1Quest Clin. Res., San Francisco, CA; 2IDC Res., Altamonte Springs, FL; 3Rancho Mirage, CA; 4Ft. Lauderdale, Fl; 5Trimeris, Inc., Durham, NC; and 6Hoffmann-La Roche, Nutley, NJ
| ||
| 419-W. | The Effect of Different HAART Regimens on Slope of Viral Rebound in HIV-Infected Patients Failing Therapy N. Press*, R. Woods, J. Raboud, P. R. Harrigan, and J. G. S. Montaner for the INCAS AVANTI and CNAAB3005 Study Teams Canadian HIV Trials Network, Vancouver, BC, Canada
| ||
| 420-W. | Pharmacokinetic Parameters and Virological Response to the Combination of Lopinavir/Ritonavir (LPV/r) and Amprenavir (APV) in HIV-Infected Patients with Multiple Treatement Failures: Week-6 Results of Puzzle 1-ANRS Study G. Raguin*1, A. M. Taburet2, G. Chêne3, L. Morand-Joubert4, C. Droz3, C. Le Tiec2, F. Clavel5, and P. M. Girard4 for the Puzzle 1 Study Group 1Hosp. Croix-St-Simon; 2Hosp. Bicêtre; 3INSERM U330, Bordeaux; 4Hosp. St. Antoine; and 5Hosp. Bichat, Paris, France
| ||
| 421-W. | Virological and Immunological Benefit of a Salvage Therapy that Includes Kaletra plus Fortovase Preceded or not by Antiretroviral Therapy Interruption (TI) in Advanced HIV-Infected Patients (6-Month-Follow-up) L. Ruiz*1, E. Ribera2, A. Bonjoch11, J. Martinez-Picado1, M. Díaz2, J. Romeu1, S. Marfil1, E. Negredo1, J. García-Prado1, C. Tural1, T. Puig11, G. Sirera1, and B. Clotet1 1IrsiCaixa Fndn. and Lluita contra la SIDA Fndn., Univ. Hosp. Germans Trias i Pujol, Badalona, Spain and 2Hosp. Vall d’Hebron, Barcelona, Spain
| ||
| 422-W. | Indinavir TID vs Indinavir/Ritonavir BID in Combination with AZT/3TC for HIV Infection in Nucleoside Pretreated Patients: HIV-NAT 005 76-Week Follow Up M. Boyd*1, 3, C. Duncombe1, 3, K. Ruxrungthram1, 2, M. Khongphattanayothin1, E. Hassink1, 4, P. Srasuebkul1, J. Sangkote1, P. Reiss4, M. Stek5, J. Lange1, 4, D. A. Cooper1, 3, P. Phanuphak1, and 2 1HIV-NAT, Thailand; 2Chulalongkorn Univ., Thailand; 3Univ. of New South Wales, Sydney, Australia; 4Univ. of Amsterdam, The Netherlands; 5Merck & Co., Whitehouse Station, NJ
| ||
| 423-W. | A Prospective Study of Deep Salvage Therapy with Lopinavir/r, Amprenavir, and NRTIs: Final 24-Week Data, Pharmacokinetics, and Association of Drug Levels/Drug Susceptibility with Virologic Response F. Baldini1, M. G. Rizzo1, R. Hoetelmans2, R. Murri1, S. Di Giambenedetto1, A. Cingolani1, R. Cauda1, and A. De Luca*1 1Catholic Univ., Rome, Italy and 2Tibotec-Virco, Mechelen, Belgium
| ||
| 424-W. | The HYDILE Trial: A Quadruple Combination of Nucleoside Analog ± Hydroxyurea and IL-2 as Salvage Therapy for HIV Infection A. Lafeuillade*, G. Hittinger, S. Chadapaud, and C. Poggi Toulon, France
| ||
| 425-W. | ACTG 364: Efficacy of Nelfinavir (NFV) and/or Efavirenz (EFV) in Combination with New NRTIs in Nucleoside Experienced Subjects: Week-144 Results M. A. Albrecht*1, R. J. Bosch2, S. H. Liou2, and D. Katzenstein3 1Beth Israel Deaconess Med. Ctr., Boston, MA; 2 Harvard Sch. of Publ. Hlth., Boston, MA; and 3Stanford Univ. Med. Ctr., CA
| ||
| 426-W. | Virologic Activity of Efavirenz in Subjects who Experienced Virological Failure with Emivirine (EMV, MKC-442) K. Borroto-Esoda*1, I. Sanne2, S. Andrews3, C. Kelbe4, P. Naiker5, T. Sole6, J. Anderson1, J. Harris1, D. Kargl1, G. Painter1, F. Rousseau1, and C. Moxham1 1Triangle Pharmaceuticals Inc., Durham, NC; 2Witts Hlth. Consortium, Johannesburg, South Africa; 3Cape Town, South Africa; 4Richards Bay, South Africa; 5St. Augustine's Hosp., Durban, South Africa; and 6Frere Hosp. East London, South Africa
| ||
| 427-W. | Virological Response to Salvage Therapy at 6 Months in Patients with B or Non-B Subtypes P. Hermans*1, J-C. Schmit2, K. Kabeya1, E. O'Doherty1, S. De Wit1, B. Sommereijns1, and N. Clumeck1 1Saint-Pierre Univ. Hosp, Brussels, Belgium 2CRP-Sante, Luxembourg
|
